FDA Advisory Committee Did Not Recommend Approval of Rimonabant (ZIMULTI(R)) for Use in Obese and Overweight Patients With Associated Risks Factors
Fonte: PR Newswire - 13 Giugno

Comunicato stampa EMEA del 23/05/2007 relativo alla sicurezza cardiaca del Rosiglitazone (Avandia, Avandamet, Avaglim)
Fonte: www.emea.europa.eu - 23 Maggio

A house divided: No clear answers on rosiglitazone safety or political backstory
Fonte: theheart.org - 7 Giugno

Newly Published Data From Large Study Support Cardiovascular Safety of Avandia (rosiglitazone maleate)
Fonte: PR Newswire - 6 Giugno

RECORD interim analysis of rosiglitazone safety: No clear-cut answers
Fonte: theheart.org - 5 Giugno

GlaxoSmithKline Response to New England Journal of Medicine Editorials
Fonte: PR Newswire - 5 Giugno

Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Fonte: PR Newswire - 5 Giugno

Rosiglitazone meta-analysis continues to drive controversy in second week
Fonte: theheart.org - 30 Maggio

Data Affirms Avandia (Rosiglitazone maleate) Cardiovascular Safety Profile
Fonte: PR Newswire - 30 Maggio

The rosiglitazone aftermath: Legitimate concerns or hype?
Fonte: theheart.org - 24 Maggio

FDA Issues Safety Alert on Avandia
Fonte:FDA News - 21 Maggio

Statement from the American College of Cardiology, American Diabetes Association and American Heart Association Related to NEJM article, 'Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes'
Fonte: PR Newswire - 21 Maggio

GlaxoSmithKline Responds to NEJM Article on Avandia
Fonte: PR Newswire - 21 Maggio

GlaxoSmithKline Strongly Defends its Record on Avandia
Fonte: PR Newswire - 21 Maggio

Cleveland Clinic Study Shows Commonly Used Diabetes Drug Increases Risk of Heart Attack and Cardiovascular Death
Fonte: PR Newswire - 21 Maggio

Rosiglitazone increases MI and CV death in meta-analysis
Fonte: theheart.org - 21 Maggio

Findus Launches MEGAO3 Omega-3 Supplement With The David Beckham Academy Globally
Fonte: PR Newswire - 29 Marzo

Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to Include Ezetimibe Efficacy Data
Fonte: PR Newswire - 28Marzo

European Union CHMP Recommends Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease: REMICADE(R)
Fonte: PR Newswire - 26 Marzo

Study Presented at ACC Shows Treatment With ISIS 301012 Added to Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C Levels of Less Than 70 mg/dL
Fonte: PR Newswire - 26 Marzo

Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients Presented at ACC
Fonte: PR Newswire - 26 Marzo

New Data Presented at ACC Show ISIS 301012 Monotherapy Reduces apoB to Undetectable Levels and Reduces LDL-C 70%
Fonte: PR Newswire - 25 Marzo

Framingham risk tool inadequate predictor of CV events in chronic/severe kidney disease patients
Fonte: theheart.org - 16 Marzo

Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
Fonte: PR Newswire - 12 Marzo

Lipitor Receives FDA Approval for Five New Indications in Patients With Heart Disease
Fonte: PR Newswire - 7 Marzo

FDA approves aliskiren: First new antihypertensive on the market in more than 10 years
Fonte: theheart.org - 6 Marzo

LifeCycle Pharma Announces Approval of its LCP-FenoChol product Will Not be Subject to a So-Called 30-month Stay Under the Hatch-Waxman Act
Fonte: PR Newswire - 6 Marzo

Tekturna(R) - The First New Type of High Blood Pressure Medicine In More Than a Decade - Receives Its First Approval in the US -
Fonte: PR Newswire - 6 Marzo

Task Force Recommends Against Use of Aspirin and Non-Steroidal Anti-Inflammatory Drugs to Prevent Colorectal Cancer
Fonte: PR Newswire - 5 Marzo